Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Christopher R. Trevino"'
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 31, Iss , Pp 101156- (2023)
We report partial response (PR) to novel therapy with selumetinib in a patient with neurofibromatosis type 2 (NF2). A 25-year-old male presented with bilateral vestibular schwannomas, spinal cord intramedullary ependymomas, cranial and spinal meningi
Externí odkaz:
https://doaj.org/article/95e7d6ef8f1741fda360afa0a45f1cbd
Autor:
Albert Jang, Ellen B. Jaeger, Elisa M. Ledet, John Xie, Brian E. Lewis, Jodi L. Layton, Oliver Sartor, Pedro C. Barata, Christopher R. Trevino
Publikováno v:
Clinical Genitourinary Cancer. 21:e9-e18
Prostate cancer (PC) rarely metastasizes to the central nervous system (CNS). In this retrospective single-institution study at a tertiary cancer center, we aimed to evaluate the clinical and genetic characteristics of advanced PC patients with CNS m
Publikováno v:
Neuroimmunology and Neuroinflammation. 2020
Autor:
Noah Kolb, Christopher R Trevino, Alissa A. Thomas, Kara K. Landry, Waqar Waheed, Fatemeh Sobhani, Mike Hehir
Publikováno v:
Muscle & Nerve. 58:10-22
Immune checkpoint inhibitor (ICPI) therapy unleashes the body's natural immune system to fight cancer. ICPIs improve overall cancer survival, however, the unbridling of the immune system may induce a variety of immune-related adverse events. Neuromus
Autor:
Carlos Kamiya-Matsuoka, Monica Loghin, Joo Yeon Nam, Rebecca Harrison, Nicholas Metrus, W. K. Alfred Yung, Kathy Hunter, Ahmad Daher, Christopher R Trevino, Marta Penas-Prado, Nazanin Majd, Kristin Alfaro, Barbara O’Brien, John de Groot, Stefania Maraka, Shiao-Pei Weathers
BACKGROUND: Glioblastoma (GBM) is the most common glioma, with an incidence of 3.2 per 100,000 adults, and approximately 12,500 new diagnoses each year in the US. With limited treatment options, there is a constant push to improve patient outcome by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e74da4cf41e16817e762a847d753ea08
https://europepmc.org/articles/PMC6216910/
https://europepmc.org/articles/PMC6216910/
Autor:
Noah A, Kolb, Christopher R, Trevino, Waqar, Waheed, Fatemeh, Sobhani, Kara K, Landry, Alissa A, Thomas, Mike, Hehir
Publikováno v:
Musclenerve.
Immune checkpoint inhibitor (ICPI) therapy unleashes the body's natural immune system to fight cancer. ICPIs improve overall cancer survival, however, the unbridling of the immune system may induce a variety of immune-related adverse events. Neuromus
Autor:
Marta Penas-Prado, Monica Loghin, Ivo W. Tremont-Lukats, Christa Seligman, Sudhakar Tummala, John de Groot, Dibaj Seyedeh, Christopher R Trevino, Barbara O’Brien, Shanta Peinado, Morris D. Groves, Rashmi Krishna Murthy, Shiao-Pei Weathers, Sherise D. Ferguson, Rebecca Harrison, Carlos Kamiya-Matsuoka, Kaylyn D Sinicrope, Pedro C. Barata, Julie Walker
Publikováno v:
Neuro-oncology Advances
BACKGROUND: Leptomeningeal metastasis (LM) is a devastating complication of cancer resulting in progressive neurologic decline. Although intrathecal (IT) methotrexate and cytarabine are commonly used for solid tumor LM, we routinely use IT topotecan
Autor:
Christopher R Trevino, Minjeong Park, Shiao-Pei Weathers, Garret L. Wiliford, Jacob Mandel, Gemma Hallatt, Tim Overeen, Kristin Alfaro-Munoz, John de Groot, Diane D. Liu
Publikováno v:
Journal of Clinical Oncology. 37:2063-2063
2063 Background: Treatment for oligodendroglioma in the molecular era is based on trials that used histologic criteria alone and has evolved over time to include observation and a combination of radiation (RT) and chemotherapy. In particular, treatme
Autor:
Juan Ruiz-Morales, Marta Penas-Prado, Arnold C. Paulino, Jose Perez-Regadera, Christopher R Trevino
Publikováno v:
Neuro-Oncology. 20:vi229-vi229
BACKGROUND: The mechanisms of neurotoxicity from radiation therapy include vascular injury, oxidative damage to neural stem cells and oligodendrocytes, and demyelination, though the pathophysiology is not fully understood. METHODS/PATIENTS: We presen